DR. JEFFREY T. YORIO MD NPI 1215197314

NPI Details

DR. Jeffrey T. Yorio, MD is a hematology and oncology internal medicine in Austin, TX with 18 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Jeffrey T. Yorio, MD NPI is 1215197314. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL SCHOOL AT DALLAS
Graduation Year:2008

The provider's business location address is:

6204 BALCONES DR
AUSTIN, TX
ZIP 78731-214
Phone: (512) 427-9400
Fax: (512) 342-2723

The NPI 1215197314 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Magnesium level (HCPCS:83735)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Unclassified drugs (HCPCS:J3490)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Ct scan of chest with contrast (HCPCS:71260)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Ferritin (blood protein) level (HCPCS:82728)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (HCPCS:86320)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Drawing of blood for a medical problem (HCPCS:99195)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Red blood count automated, with additional calculations (HCPCS:85046)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev (HCPCS:G6012)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Folic acid level, serum (HCPCS:82746)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)

The enumeration date for this NPI number is 6/11/2008 and was last updated on 11/15/2017.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.